Joanne Holland
Technik-/Wissenschafts-/F&E-Leiter bei CONDUIT PHARMACEUTICALS INC.
Aktive Positionen von Joanne Holland
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CONDUIT PHARMACEUTICALS INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.03.2024 | - |
Karriereverlauf von Joanne Holland
Ehemalige bekannte Positionen von Joanne Holland
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Nuformix Technologies Ltd.
 Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Direktor/Vorstandsmitglied | - | 31.05.2021 |
| Technik-/Wissenschafts-/F&E-Leiter | - | 31.05.2021 | |
| NUFORMIX PLC | Direktor/Vorstandsmitglied | 01.01.2008 | 31.05.2021 |
| Technik-/Wissenschafts-/F&E-Leiter | 01.01.2008 | 24.05.2021 | |
| Gründer | 01.01.2008 | 31.05.2021 |
Ausbildung von Joanne Holland
| University of Leeds | Doctorate Degree |
Statistik
International
| Vereinigtes Königreich | 4 |
| Vereinigte Staaten | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NUFORMIX PLC | Health Technology |
| CONDUIT PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Nuformix Technologies Ltd.
Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Joanne Holland
- Erfahrung
